Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer
Fig 2
Characterization of TSC1 and TSC2 deficient cell lines.
Immunoblots of TSC1 and TSC2 deficient cell lines were performed to examine multiple components of the mTORC1 signaling pathway. Cells were serum starved for 24h (−) or had serum add back for 30 min (+) after starvation. CAL-72 and PEER cells showed no TSC1 and reduced TSC2 expression. SNU-878, SNU-886, and SNU-398 showed an absence of TSC2 expression. pS6K (Thr389), pS6 (Ser235/236 and Ser240/244) p4E-BP1 (Thr37/46), and pEIF2 (Ser51) showed a strong expression in a serum starved condition in all TSC1 or TSC2 deficient cell lines, indicating constitutive mTORC1 activation. GAPDH and BIP were used as loading controls.